Chemours Co
Form 424B5
May 21, 2018
TABLE OF CONTENTS
Filed Pursuant to Rule 424(b)(5)
Registration Statement No. 333-217642

The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED MAY 21, 2018
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus Dated May 4, 2017)

The Chemours Company
€ % Senior Notes due 2026

The Chemours Company ("Chemours," "we" or "us") is offering € in aggregate principal amount of its % senior notes due 2026 (the "notes"). We will pay interest on the notes, semi-annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2018. The notes will mature on May 15, 2026.

We may redeem the notes, in whole or in part, from time to time at our option, prior to May 15, 2021, at prices equal to 100% of the aggregate principal amount of the notes to be redeemed, plus the "make-whole" premium and accrued and unpaid interest, if any, to, but excluding, the redemption date. At any time prior to May 15, 2021, we may redeem up to 35% of the notes using the net proceeds from certain equity offerings. See "Description of the Notes — Optional Redemption." In addition, we may redeem the notes, at our option, in whole but not in part, in the event of certain developments affecting United States taxation as described under "Description of the Notes — Redemption of the Notes for Tax Reasons." If a Change of Control Repurchase Event (as defined herein) occurs, unless we have exercised our option to redeem the notes, we will be required to offer to purchase the notes on the terms described under "Description of the Notes — Offer to Purchase Upon Change of Control Repurchase Event." We may from time to time purchase the notes in the open market or otherwise.

The notes will be our senior unsecured obligations, rank pari passu in right of payment with all of our existing and future senior unsecured indebtedness and rank senior in right of payment to all of our future subordinated indebtedness. The notes will be fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by each of our existing and future direct and indirect domestic restricted subsidiaries that incurs or guarantees indebtedness under our New Senior Secured Facilities (as defined herein) or guarantees certain other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100 million (collectively, the "guarantors"). Any such subsidiary guarantee of the notes may be released under certain circumstances, including upon the release or discharge of such subsidiary from all of its credit facility indebtedness and certain other indebtedness, as described under "Description of the Notes — Subsidiary Guarantees." The notes will be effectively subordinated to our existing and future secured indebtedness, including borrowings under our New Senior Secured Facilities, to the extent of the value of the collateral securing such secured indebtedness, and will be structurally subordinated to the liabilities of any non-guarantor subsidiaries.

We will issue the notes in minimum denominations of €100,000 and integral multiples of €1,000 in excess thereof. There will be no sinking fund for the notes. We intend to apply to the Irish Stock Exchange for the notes to be admitted to the Official List of the Irish Stock Exchange and traded on the Global Exchange Market.

Investing in the notes involves risks. See "Risk Factors" beginning on page S-11.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete.

Any representation to the contrary is a criminal offense.

	Per Note	Total
Public Offering Price(1)	%	€
Underwriting Discount	%	€
Proceeds to Chemours (before expenses)	%	€

(1)
Plus accrued interest, if any, from , 2018 if settlement occurs after that date.

Delivery of the notes in book-entry form will be made on or about , 2018 only through Euroclear System (“Euroclear”) and Clearstream Banking, S.A. (“Clearstream”).

Joint Book-Running Managers

Citigroup J.P. Morgan Barclays

Credit Suisse HSBC RBC Capital Markets

BofA Merrill Lynch Deutsche Bank Securities

Senior Co-Managers

Mizuho Securities TD Securities

Co-Managers

SunTrust Robinson Humphrey

BNP PARIBAS

Citizens Capital Markets

Prospectus Supplement dated , 2018

TABLE OF CONTENTS

TABLE OF CONTENTS

Prospectus Supplement

	Page
About this Prospectus Supplement	S-1
Forward-Looking Statements	S-2
Summary	S-4
The Offering	S-8
Risk Factors	S-11
Currency Conversion	S-17
Consolidated Ratio of Earnings to Fixed Charges	S-18
Use of Proceeds	S-19
Capitalization	S-20
Description of Other Indebtedness	S-22
Description of the Notes	S-25
Supplemental U.S. Federal Income Tax Considerations	S-53
Supplemental ERISA Considerations	S-54
Underwriting	S-58
Validity of the Notes	S-62
Experts	S-62
Where You Can Find More Information	S-62
Prospectus	
About this prospectus	1
Prospectus summary	2
Risk factors	5
Use of proceeds	8
Ratios of earnings to fixed charges	8
Description of debt securities	9
Description of warrants	27
Description of preferred stock	30
Description of common stock	32
Registration and settlement	33
Description of other indebtedness	40
U.S. federal income tax considerations	43
Plan of distribution	63
ERISA considerations	65
Where you can find more information	68
Forward-looking statements	69
Legal matters	71
Experts	71

You should rely only on the information contained in or incorporated by reference into this prospectus supplement and the accompanying prospectus or information contained in a free writing prospectus that we authorize to be delivered to you. This prospectus supplement and the accompanying prospectus may be used only for the purpose for which they have been prepared. No one is authorized to give information other than that contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or any free writing prospectus that we authorize to be delivered to you. We have not, and the underwriters have not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it.

We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information appearing in this prospectus supplement, the accompanying prospectus or any document incorporated by reference herein or therein is accurate as of any date other than the date of the applicable document. Our business, financial condition, results of operations and prospects may have changed since that date. Neither this prospectus supplement nor the accompanying prospectus constitutes an offer, or an invitation on our behalf or on behalf of the underwriters, to subscribe for and purchase any of the securities and may not be used for or in connection with an offer or solicitation by anyone, in any jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation.

TABLE OF CONTENTS

Notice to Prospective Investors in the European Economic Area

Neither this prospectus supplement nor the accompanying prospectus is a prospectus for the purposes of the European Union's Directive 2003/71/EC (as amended, including by Directive 2010/73/EU, the "Prospective Directive"), as implemented in the Member States of the European Economic Area (the "EEA").

PRIIPs Regulation / Prohibition of sales to EEA retail investors — The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU, as amended ("MiFID II") or (ii) a customer within the meaning of Directive 2002/92/EC, as amended (the "Insurance Mediation Directive"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently, no key information document required by Regulation (EU) No 1286/2014, as amended (the "PRIIPs Regulation") for offering or selling the notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

Notice to Prospective Investors in the United Kingdom

The communication of this prospectus supplement, the accompanying prospectus and any other document or materials relating to the issue of the notes offered hereby is not being made, and the contents of such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdom's Financial Services and Markets Act 2000, as amended (the "FSMA"). Accordingly, such documents and/or materials are not being distributed to or otherwise communicated with, and must not be passed on to, any person in the United Kingdom except in circumstances in which section 21(1) of FSMA will not apply. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom who have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), or who fall within Article 49(2)(a) to (d) of the Financial Promotion Order, or who are any other persons to whom it may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, the notes offered hereby are only available to, and any investment or investment activity to which this prospectus supplement and the accompanying prospectus relate will be engaged in only with, relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this prospectus supplement or the accompanying prospectus or any of their contents.

Extended Settlement Notice

We expect that delivery of the notes will be made to investors on or about , 2018, which will be the business da following the date of this prospectus supplement (such settlement being referred to as "T+ "). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially settle in T+ , to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to their date of issuance hereunder should consult their advisors.

TABLE OF CONTENTS

About this prospectus supplement

We provide information to you about the notes in two separate documents: (1) this prospectus supplement, which describes the specific terms of the notes and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference in that prospectus, and (2) the accompanying prospectus, which provides general information about securities we may offer from time to time, including securities other than the notes that are being offered by this prospectus supplement. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on the information in this prospectus supplement.

It is important for you to read and consider all of the information contained in this prospectus supplement and the accompanying prospectus in making your investment decision. You also should read and consider the information in the documents we have referred you to in "Where You Can Find More Information" on page S-62 of this prospectus supplement and page 68 of the accompanying prospectus, which are incorporated by reference in this prospectus supplement and the accompanying prospectus, respectively.

We include cross-references in this prospectus supplement and the accompanying prospectus to captions in these materials where you can find additional related discussions. The table of contents in this prospectus supplement provides the pages on which these captions are located.

Unless otherwise indicated or the context otherwise requires, references in this prospectus to "The Chemours Company," "Chemours," "we," "us," "our" and "our company" refer to The Chemours Company and its consolidated subsidiar

TABLE OF CONTENTS

Forward-looking statements

Information we have included or incorporated by reference in this prospectus supplement and the accompanying prospectus contains or may contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words "believe," "expect," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally ident "forward-looking statements," which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the risks, uncertainties and other factors discussed below and in the section titled "Risk Factors" in this prospectus supplement and the forward-looking statements and risk factor sections in our Annual Report on Form 10-K for the year ended December 31, 2017 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties, many of which are beyond our control. Important factors that may materially affect such forward-looking statements and projections include:

- fluctuations in energy and raw materials pricing;
- failure to develop and market new products and applications, and optimally manage product life cycles;
- significant litigation and environmental matters, including indemnifications we were required to assume;
- significant or unanticipated expenses, including, but not limited to, litigation or legal settlement expenses;
- increased competition and increasing consolidation of our core customers;
- changes in relationships with our significant customers and suppliers;
- failure to manage process safety and product stewardship issues appropriately;
- global economic and capital markets conditions, such as inflation, interest and currency exchange rates, and commodity prices, as well as regulatory requirements;
- currency-related risks;
- our current indebtedness and availability of borrowing facilities, including access to our revolving credit facilities;
-

business or supply disruptions and security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters;

- uncertainty regarding the availability of additional financing in the future, and the terms of such financing;

- negative rating agency actions;

- changes in laws and regulations or political conditions;

- ability to protect, defend and enforce our intellectual property rights;

- our ability to predict, identify and address changes in consumer preference and demand;

- our ability to complete potential divestitures or acquisitions and our ability to realize the expected benefits of divestitures or acquisitions if they are completed;

- our ability to deliver cost savings as anticipated, whether or not on the timelines proposed;

TABLE OF CONTENTS

- our ability to meet our growth expectations through 2020;
- our ability to pay a dividend and the amount of any such dividend declared; and
- disruptions in our information technology networks and systems.

Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. We assume no obligation to revise or update any forward-looking statement for any reason, except as required by law.

TABLE OF CONTENTS

Summary

The following summary should be read together with the information contained in other parts of this prospectus supplement and in the accompanying prospectus, including the documents that we refer to and incorporate by reference herein. This summary highlights selected information from this prospectus supplement and the accompanying prospectus to help you understand the offering the notes. You should read this prospectus supplement and the accompanying prospectus, including the documents we incorporate by reference herein, carefully to understand fully the terms of the notes as well as the other considerations that are important to you in making a decision about whether to invest in the notes. You should pay special attention to the “Risk Factors” section beginning on page S-11 of this prospectus supplement and the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 to determine whether an investment in the notes is appropriate for you.

The Chemours Company

The Chemours Company, a Delaware corporation, is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. Our principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates and titanium dioxide (“TiO_2”) pigment. We manage and report our operating results through three reportable segments: Fluoroproducts, Chemical Solutions and Titanium Technologies. Our Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. Our Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrials, and consumer applications. Our Titanium Technologies segment is a leading, global producer of TiO_2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.

We operate 26 production facilities located in 10 countries and serve approximately 4,000 customers across a wide range of end markets in nearly 130 countries.

The following chart sets forth the global sales of our businesses for the years ended December 31, 2017, 2016, and 2015:

(1)
Europe, the Middle East, and Africa (EMEA).

(2)
Latin America includes Mexico.

We are committed to creating value for our customers through the reliable delivery of high quality products and services around the globe. We create value for our customers and stockholders through: (i) operational excellence and asset efficiency, which includes our commitment to safety and environmental stewardship; (ii) strong customer focus to produce innovative, high performance products; (iii) focus on cash flows generation through optimization of our cost structure, and improvement in working capital and

supply chain efficiencies through our transformation plan (described below); (iv) organic growth and inorganic expansions to current business; and, (v) creation of an organization that is committed to our corporate values of safety, customer appreciation, simplicity, collective entrepreneurship, and integrity.

Many of our commercial and industrial relationships span decades. Our customer base includes a diverse set of companies, many of which are leaders in their respective industries. Our sales are not materially dependent on any single customer. As of December 31, 2017, no one individual customer balance represented more than 5% of our total outstanding receivables balance and no one individual customer represented more than 10% of our net sales.

Segments

In our Titanium Technologies segment, we have a long-standing history of delivering high quality TiO2 pigment using our proprietary chloride technology. We are one of the largest global producers of TiO2, and our low cost network of manufacturing facilities allows us to efficiently and cost-effectively serve our global customer base. During 2016, we further enhanced our operating cost advantage with the startup of a second production line at our Altamira, Mexico facility. We believe we are well-positioned to remain one of the lowest cost TiO2 producers and continue to meet our customers' growing needs around the world.

In our Fluoroproducts segment, we are one of two globally-integrated producers making both fluorochemicals and fluoropolymers. In our fluorochemicals business, we expect to see increased adoption of Opteon™, one of the world's lowest global warming potential ("GWP") refrigerants, as governments around the world pass legislation that makes the use of low GWP refrigerants a requirement. Our fluoropolymers offerings provide customers with tailored products that have unique properties, including very high temperature resistance and high chemical resistance. We will continue to invest in research and development ("R&D") to remain a leader in these areas and ensure that we are able to meet our customers' needs as regulations change.

In our Chemical Solutions segment, we completed a strategic review of our portfolio in 2016, which included the announced sales of our aniline facility in Beaumont, Texas, our Clean & Disinfect ("C&D") business, and our Sulfur products business, as well as ceasing production at our Reactive Metals Solutions ("RMS") facility in Niagara Falls, New York. We remain committed to retaining and improving our Mining Solutions business (previously known as our Cyanides business) and the product lines at our Belle, West Virginia site. As the largest global producer of solid sodium cyanide, our Mining Solutions business is recognized for our quality product offering, reliability of supply, and commitment to the safe production, storage, and use of our products.

Company Information

Our headquarters are located at 1007 Market Street, Wilmington, Delaware 19899, and our telephone number is (302) 773-1000. Our website is www.chemours.com. The information on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus.

Recent Developments

New Senior Secured Credit Facilities

On April 3, 2018, we entered into an amended and restated credit agreement among us, the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the "New Credit Agreement"), which amended and restated, in its entirety, the Prior Credit Agreement (as defined below) and provides for a seven-year, senior secured term loan facility ("New Senior Secured Term Loan Facility"), and a five-year, $800 million senior secured revolving credit facility ("New Senior Secured Revolving Credit Facility"). The New Senior Secured Term Loan Facility and the New Senior Secured Revolving Credit Facility are referred to collectively as the "New Senior Secured Facilities."

The New Senior Secured Term Loan Facility provides for a class of term loans denominated in U.S. dollars, in an aggregate principal amount of $900 million ("New Dollar Term Loan") and a class of term loans denominated in euros, in an aggregate principal amount of €350 million ("New Euro Term Loan").

TABLE OF CONTENTS

The New Dollar Term Loan and the New Euro Term Loan are referred to collectively as the “New Senior Secured Term Loans.” The New Dollar Term Loan bears a variable interest rate equal to, at our election, adjusted LIBOR plus 1.75%, subject to a LIBOR floor of 0.00% or adjusted base rate plus 0.75%, subject to a base rate floor of 1.00%. The New Euro Term Loan bears a variable interest rate equal to adjusted EURIBOR plus 2.00%, subject to a EURIBOR floor of 0.50%. The New Senior Secured Term Loans will mature on April 3, 2025 and the loans under the New Senior Secured Revolving Credit Facility will mature on April 3, 2023, in each case, subject to acceleration in certain circumstances.

The New Credit Agreement also modified certain provisions of the Prior Credit Agreement, including certain negative covenants to allow further flexibility for us. The New Senior Secured Facilities contain affirmative and negative covenants, representations and warranties and other terms customary for financings of this type.

Our obligations under the New Senior Secured Facilities are guaranteed on a senior secured basis by all of our material, wholly-owned domestic subsidiaries, which are also the guarantors of the notes, subject to certain agreed upon exceptions. The obligations under the New Senior Secured Facilities are also, subject to certain agreed upon exceptions, secured by a first priority lien on substantially all of our assets and substantially all of the assets of our material, wholly-owned domestic subsidiaries (including the guarantors of the notes), including 100% of the stock of certain of our domestic subsidiaries and 65% of the stock of certain of our foreign subsidiaries.

The proceeds of New Senior Secured Term Loans, together with cash on hand, were used to prepay in full all outstanding amounts (as of April 3, 2018, approximately $921 million under the dollar term loan and approximately €393 million under the euro term loan) under our prior Credit Agreement, dated as of May 12, 2015, among us, the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent (as amended, the “Prior Credit Agreement”). The proceeds of the New Senior Secured Term Loans were also used to pay fees and expenses in connection with the foregoing and with the other transactions contemplated under the New Credit Agreement and the remaining proceeds will be used for working capital and other general corporate purposes. The proceeds of the New Senior Secured Revolving Credit Facility may be used for working capital and other general corporate purposes and other transactions not prohibited by the New Credit Agreement. The entry into the New Credit Agreement and the prepayment of all outstanding amounts and termination of all commitments under our Prior Credit Agreement are referred to collectively as the “Refinancing Transaction.” As a result of the Refinancing Transaction, we reduced our outstanding term loan principal amount by approximately $75 million, based on the exchange rate at the time the Refinancing Transaction was completed.

Concurrent Tender Offers and Redemption

Concurrently with the launch of this offering, we commenced cash tender offers for up to $250 million of our outstanding 6.625% senior notes due 2023 (the “existing 2023 dollar notes”) and any and all of our outstanding 6.125% senior notes due 2023 (the “existing 2023 euro notes” and, together with the existing 2023 dollar notes, the “existing 2023 notes”), and solicitations of consents to amend certain provisions of the indenture governing the existing 2023 notes, in each case, subject to certain conditions, including the successful completion of this offering (each a “Tender Offer” and collectively, the “Tender Offers”). The Tender Offers are expected to expire at Midnight, New York City time, on June 18, 2018, subject to extension by us. Holders of the existing 2023 notes may not tender notes in the Tender Offer without delivering consents to the proposed amendments and may not deliver such consents without tendering the related existing 2023 notes. As of March 31, 2018, we had approximately $1,158 million in aggregate principal amount of our existing 2023 dollar notes outstanding and approximately €295 million in aggregate principal amount of our existing 2023 euro notes outstanding.

Holders of the existing 2023 notes that are validly tendered (and not validly withdrawn) prior to the early tender deadline of 5:00 p.m., New York City time, on June 4, 2018, as may be extended (the “early tender expiration”), and accepted by us will receive the total consideration of $1,052.50 per $1,000 principal amount of the existing 2023 dollar notes and €1,048.75 per €1,000 principal amount of the existing 2023 euro notes, in each case plus any accrued and unpaid interest up to, but not including, the early settlement date. Holders of the existing 2023 notes that are validly tendered (and not validly withdrawn) after the early

TABLE OF CONTENTS

tender deadline, but on or prior to the expiration of the Tender Offers, and accepted by us will receive the tender offer consideration of $1,022.50 per $1,000 principal amount of the existing 2023 dollar notes and €1,018.75 per €1,000 principal amount of the existing 2023 euro notes, in each case plus any accrued and unpaid interest up to, but not including, the final settlement date. Assuming $250,000,000 of the existing 2023 dollar notes and all of the existing 2023 euro notes are validly tendered (and not validly withdrawn) prior to the early tender expiration, we would expect to complete the Tender Offers for an aggregate purchase price of $263,125,000, with respect to the existing 2023 dollar notes, including an early participation premium of $7,500,000, and €309,044,601, with respect to the existing 2023 euro notes, including an early participation premium of €8,840,370, in each case, plus accrued and unpaid interest to, but not including the early settlement date.

We may amend, extend or terminate the Tender Offers in accordance with their terms. The completion of this offering is an express condition to our obligation to purchase any existing 2023 notes tendered in the Tender Offers. However, the consummation of this offering is not conditioned on the consummation of, or reaching any minimum threshold with respect to, the Tender Offers.

In addition, concurrently with the launch of the Tender Offers and conditioned upon the consummation of this offering and the failure to receive the requisite consents to amend the indenture governing the existing 2023 euro notes pursuant to the applicable Tender Offer, we issued a notice of redemption for any existing 2023 euro notes that remain outstanding following the consummation or termination of the applicable Tender Offer (the "2023 Euro Notes Redemption"). Any such 2023 Euro Notes Redemption will be made in accordance with the terms of the indenture governing the existing 2023 euro notes, as may be amended by the solicitation of consents pursuant to the applicable Tender Offer, which provides for a redemption price on or after May 15, 2018 and prior to May 15, 2019 equal to 104.594%, plus accrued and unpaid interest thereon to the redemption date.

We intend to use a portion of the net proceeds from this offering to fund the purchase price and accrued and unpaid interest payable with respect to all of the existing 2023 euro notes and a portion of the existing 2023 dollar notes validly tendered and accepted for purchase pursuant to the Tender Offers and, if applicable, the 2023 Euro Notes Redemption. We intend to cancel all of the existing 2023 euro notes that are purchased in the Tender Offers or redeemed in the 2023 Euro Notes Redemption and, upon such cancellation, such existing 2023 notes will no longer remain outstanding obligations of Chemours. We also intend to cancel a portion of the existing 2023 dollar notes that are purchased in the Tender Offers, and upon such cancellation for such existing 2023 dollar notes will no longer remain outstanding obligations of Chemours.

The foregoing description of the Tender Offers and the 2023 Euro Notes Redemption is provided for informational purposes only, and this prospectus supplement does not constitute an offer to buy or the solicitation of an offer to sell, or a notice of redemption of, any of the existing 2023 notes. The Tender Offers are being made only by and pursuant to the terms of the applicable Offer to Purchase and Consent Solicitation Statement and, with respect to the existing 2023 dollar notes, a related letter of transmittal and consent. Any 2023 Euro Notes Redemption will only be made in accordance with the provisions of the indenture governing the existing 2023 euro notes, as may be amended from time to time.

Citigroup Global Markets Inc. is acting as dealer manager for the Tender Offers, for which it will receive indemnification against certain liabilities and reimbursement of expenses. Additionally, certain of the underwriters or their affiliates are holders of our existing 2023 notes and, accordingly, may receive a portion of the proceeds of this offering as a result of the Tender Offers and/or the 2023 Euro Notes Redemption, as applicable.

The offering

The following is a brief summary of some of the terms of the offering. For a more complete description of the terms of the notes, please refer to “Description of the Notes” in this prospectus supplement and “Description of debt securities” in the accompanying prospectus. You should read carefully this entire prospectus supplement and the accompanying prospectus for a more complete understanding of us and the offering.

Issuer

The Chemours Company, a Delaware corporation.

Securities Offered

€ aggregate principal amount of % senior notes due 2026.

Maturity Date

The notes will mature on May 15, 2026.

Interest Rate

The notes will bear interest at the rate of % per year from the original issuance date.

Interest Payment Date

We will pay interest on the notes, semi-annually in arrears on May 15 and November 15 of each year. We will make the first interest payment on the notes on November 15, 2018.

Guarantees

The notes will be fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by each of our existing and future direct and indirect domestic Restricted Subsidiaries (as defined in “Description of the Notes”) that (a) incurs or guarantees indebtedness under the New Senior Secured Facilities or (b) guarantees other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100 million. The guarantees of the notes will rank equally with all other senior indebtedness of the guarantors. None of our foreign subsidiaries or holding companies thereof will guarantee the notes and no foreign subsidiaries or such holding companies are expected to guarantee the notes in the future. The guarantees are subject to release under certain circumstances, including upon the release or discharge of such subsidiary from all of its credit facility indebtedness and certain other indebtedness, as described in this prospectus supplement. See “Description of the Notes — Subsidiary Guarantees.”

Ranking

The notes and the guarantees thereof will be our and the guarantors’ senior unsecured obligations and will be:

- effectively subordinated to any of our and the guarantors’ existing or future secured indebtedness (including existing and future obligations under the New Senior Secured Facilities) to the extent of the value of the collateral securing such secured indebtedness;

- structurally subordinated to all existing and future liabilities, including trade payables, of each of our and the guarantors’ non-guarantor subsidiaries;

- pari passu in right of payment with all of our and the guarantors’ existing and future senior unsecured indebtedness; and

- senior in right of payment to all of our and the guarantors’ future subordinated indebtedness.

As of March 31, 2018, on an adjusted basis, after giving effect to the Refinancing Transaction, this offering of the notes and the

TABLE OF CONTENTS

application of the net proceeds from this offering, as set forth under "Capitalization," we would have had approximately $ million of indebtedness outstanding, including $1,334 million outstanding under our New Senior Secured Term Loan Facility, $ million of outstanding senior notes (including the notes offered hereby) and full borrowing capacity of $800 million under our New Senior Secured Revolving Credit Facility. Euro amounts included in U.S. dollars in the previous sentence were converted based on a euro/U.S. dollar exchange rate of €1.00 = U.S.$1.2389 as of March 31, 2018.

Optional Redemption

At any time prior to May 15, 2021, we may redeem all or a part of the notes, at redemption prices equal to 100% of the aggregate principal amount of the notes to be redeemed plus the "make-whole" premium, and accrued and unpaid interest, if any, to, but excluding, the redemption date.

At any time prior to May 15, 2021, we may redeem up to 35% of the aggregate principal amount of the notes, with the net cash proceeds of one or more Equity Offerings (as defined in "Description of the Notes") at a price equal to % of the principal amount of such notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

On or after May 15, 2021, we may redeem the notes, in whole or in part, at the redemption prices set forth under "Description of the Notes — Optional Redemption" plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

Offer to Purchase Upon Change of Control Repurchase Event

If we experience a "Change of Control Repurchase Event" (as defined in "Description of the Notes"), unless we have exercised our option to redeem the notes, we will be required to offer to repurchase the notes at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to, but excluding, the date of purchase. See "Description of the Notes — Offer to Purchase upon Change of Control Repurchase Event."

Additional Amounts

We will, subject to certain exceptions and limitations, pay additional amounts on the notes to a holder who is not a United States person (as defined under "Description of the Notes — Payment of Additional Amounts on the Notes") in respect of any required withholding or deduction for any present or future tax, assessment or other governmental charge imposed by any taxing authority in the United States, as will result in receipt by holders of notes that are not United States persons of such amounts as they would have received had no such withholding or deduction been required. See "Description of the Notes — Payment of Additional Amounts on the Notes."

Redemption of Notes for Tax Reasons

We may redeem the notes, in whole but not in part, at 100% of the aggregate principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the

TABLE OF CONTENTS

redemption date, in the event of certain changes in the tax laws of the United States that would require us to pay additional amounts as described under “Description of the Notes — Redemption of the Notes for Tax Reasons.”

Covenants

The indenture governing the notes will contain covenants that, among other matters, limit:

•